Recent News

• 03.30.2026 - Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
• 01.29.2026 - Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
• 01.29.2026 - Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Recent Filings

• 03.19.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 03.19.2026 - EFFECT Notice of Effectiveness
• 03.17.2026 - S-3/A Registration statement under Securities Act of 1933
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.16.2026 - 8-K Current report
• 03.16.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 03.16.2026 - EX-99.1 EX-99.1
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2026 - S-3 Registration statement under Securities Act of 1933